Short answer
Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026.
Entrada Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026
- Financial details and corporate updates contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $42.8M, or $1.01 per share, versus $43.1M and $1.04 in Q2 2025
- Cash, equivalents and marketable securities $223.0M, down from $295.7M, funding operations into Q3 2027
- ELEVATE-45-201 Cohort 1 data expected October 2026, with Cohort 2 dosing ongoing at 10 mg/kg
- ELEVATE-44-201 Cohort 1 open-label data expected by year-end 2026, Cohort 2 data in Q1 2027
- Vertex VX-670 Phase 1/2 DM1 data expected in H2 2026, providing a partnered clinical catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Entrada Therapeutics, Inc. 8-K filings
Get the next TRDA 8-K as it lands
Follow TRDA for push alerts, or ask the research agent what this filing means.